FDA Accepts NDA for New Formulation of PSMA PET Injection in Prostate Cancer
Written by
Cancer Network
Published
0
comments
0
min
The new formulation should increase the batch size by approximately 50% and will offer the potential to expand access to patients in new geographic locations.